In Brief: Pharmacia & Upjohn OTC Rogaine Extra Strength
Executive Summary
Pharmacia & Upjohn OTC Rogaine Extra Strength: FDA's Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees recommend OTC approval of 5% strength minoxidil solution for men July 16. P&U initially submitted an NDA in December 1995 as an Rx product, which was deemed "approvable" a year later. In February P&U proposed that the 5% product go OTC directly. Committees determine P&U claim that Rogaine 5% produces "more hair growth" than the currently marketed 2% product is supported, but P&U claim that the 5% solution leads to "faster" hair growth needs further data. P&U is pursuing approval of Rogaine Extra Strength for women separately...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth